NO830115L - Fremgangsmaate ved fremstilling av 3-(1h-tetrazol)-5-yl)-4(3h)-kinazolinoner - Google Patents
Fremgangsmaate ved fremstilling av 3-(1h-tetrazol)-5-yl)-4(3h)-kinazolinonerInfo
- Publication number
- NO830115L NO830115L NO830115A NO830115A NO830115L NO 830115 L NO830115 L NO 830115L NO 830115 A NO830115 A NO 830115A NO 830115 A NO830115 A NO 830115A NO 830115 L NO830115 L NO 830115L
- Authority
- NO
- Norway
- Prior art keywords
- tetrazol
- formula
- benzamide
- methyl
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 150000002905 orthoesters Chemical class 0.000 claims abstract description 8
- GOXQERQFQMSLJU-UHFFFAOYSA-N 2-amino-n-(2h-tetrazol-5-yl)benzamide Chemical compound NC1=CC=CC=C1C(=O)NC1=NN=NN1 GOXQERQFQMSLJU-UHFFFAOYSA-N 0.000 claims abstract description 5
- GPEZBOYWAXXHJE-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical class C1=NC2=CC=CC=C2C(=O)N1C=1N=NNN=1 GPEZBOYWAXXHJE-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 6,7-methylenedioxy Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 claims description 10
- 150000003536 tetrazoles Chemical class 0.000 claims description 10
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- YOPUNQQNIGKDNB-UHFFFAOYSA-N 2-amino-5-methyl-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=C(N)C(C(=O)NC=2NN=NN=2)=C1 YOPUNQQNIGKDNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- ASFJCXAWEPFWMT-UHFFFAOYSA-N 6-amino-n-(2h-tetrazol-5-yl)-1,3-benzodioxole-5-carboxamide Chemical compound NC1=CC=2OCOC=2C=C1C(=O)NC1=NN=NN1 ASFJCXAWEPFWMT-UHFFFAOYSA-N 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- WZWQGEYKGVARIQ-UHFFFAOYSA-N 7-(2h-tetrazol-5-yl)-[1,3]dioxolo[4,5-g]quinazolin-8-one Chemical compound C1=NC2=CC=3OCOC=3C=C2C(=O)N1C1=NN=NN1 WZWQGEYKGVARIQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- 230000020477 pH reduction Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 15
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000001914 filtration Methods 0.000 description 20
- 239000000155 melt Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000001953 recrystallisation Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 238000010992 reflux Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000008018 melting Effects 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000011343 solid material Substances 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- JVSMPWHQUPKRNV-UHFFFAOYSA-N 2h-tetrazol-5-amine;hydrate Chemical compound O.NC=1N=NNN=1 JVSMPWHQUPKRNV-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 4
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical group C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 description 2
- CQMBPIZGAQMXPA-UHFFFAOYSA-N 2-amino-3-methoxy-n-(2h-tetrazol-5-yl)benzamide Chemical compound COC1=CC=CC(C(=O)NC=2NN=NN=2)=C1N CQMBPIZGAQMXPA-UHFFFAOYSA-N 0.000 description 2
- KMWONKVOSVROKG-UHFFFAOYSA-N 2-amino-3-methyl-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=CC(C(=O)NC=2NN=NN=2)=C1N KMWONKVOSVROKG-UHFFFAOYSA-N 0.000 description 2
- JPUVCSLBSXDEEK-UHFFFAOYSA-N 2-amino-5-chloro-n-(2h-tetrazol-5-yl)benzamide Chemical compound NC1=CC=C(Cl)C=C1C(=O)NC1=NN=NN1 JPUVCSLBSXDEEK-UHFFFAOYSA-N 0.000 description 2
- RJIJLJFTXLWWKO-UHFFFAOYSA-N 2-amino-6-methyl-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=CC(N)=C1C(=O)NC1=NN=NN1 RJIJLJFTXLWWKO-UHFFFAOYSA-N 0.000 description 2
- DRZACGKWDNSKMN-UHFFFAOYSA-N 2-methyl-6-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(=O)NC1=NN=NN1 DRZACGKWDNSKMN-UHFFFAOYSA-N 0.000 description 2
- ZMAJSTDJAIVHGZ-UHFFFAOYSA-N 2-methyl-6-nitrobenzoyl chloride Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(Cl)=O ZMAJSTDJAIVHGZ-UHFFFAOYSA-N 0.000 description 2
- HIKKGCYAILVAHC-UHFFFAOYSA-N 2-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)NC1=NNN=N1 HIKKGCYAILVAHC-UHFFFAOYSA-N 0.000 description 2
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 2
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 2
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 2
- XQJWBDDLVCMLAB-UHFFFAOYSA-N 6-nitro-1,3-benzodioxole-5-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC2=C1OCO2 XQJWBDDLVCMLAB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011706 wistar kyoto rat Methods 0.000 description 2
- CCXSGQZMYLXTOI-UHFFFAOYSA-N 13506-76-8 Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(O)=O CCXSGQZMYLXTOI-UHFFFAOYSA-N 0.000 description 1
- JSDCGQYIKUYIKP-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=NN=NN1 JSDCGQYIKUYIKP-UHFFFAOYSA-N 0.000 description 1
- NIJNZBARSNFQBN-UHFFFAOYSA-N 2-methyl-3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C1=NN=NN1 NIJNZBARSNFQBN-UHFFFAOYSA-N 0.000 description 1
- LWKJXTDKPUDKHT-UHFFFAOYSA-N 2-phenyl-3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical compound C=1C=CC=CC=1C1=NC2=CC=CC=C2C(=O)N1C1=NN=NN1 LWKJXTDKPUDKHT-UHFFFAOYSA-N 0.000 description 1
- ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 1
- ZYFPEILNIXSFAW-UHFFFAOYSA-N 3-methoxy-2-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound COC1=CC=CC(C(=O)NC=2NN=NN=2)=C1[N+]([O-])=O ZYFPEILNIXSFAW-UHFFFAOYSA-N 0.000 description 1
- YMOMYSDAOXOCID-UHFFFAOYSA-N 3-methoxy-2-nitrobenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1[N+]([O-])=O YMOMYSDAOXOCID-UHFFFAOYSA-N 0.000 description 1
- URDXWTRRYHFFQK-UHFFFAOYSA-N 3-methoxy-2-nitrobenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1[N+]([O-])=O URDXWTRRYHFFQK-UHFFFAOYSA-N 0.000 description 1
- RVWGHBBFAVRLMB-UHFFFAOYSA-N 3-methyl-2-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=CC(C(=O)NC=2NN=NN=2)=C1[N+]([O-])=O RVWGHBBFAVRLMB-UHFFFAOYSA-N 0.000 description 1
- GHIWEJDFSBLCBI-UHFFFAOYSA-N 5-chloro-2-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1C(=O)NC1=NNN=N1 GHIWEJDFSBLCBI-UHFFFAOYSA-N 0.000 description 1
- ZYUYCUXFKGUOSP-UHFFFAOYSA-N 5-chloro-2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1C(Cl)=O ZYUYCUXFKGUOSP-UHFFFAOYSA-N 0.000 description 1
- UXRJPOCIDAOHHW-UHFFFAOYSA-N 5-methyl-2-nitro-n-(2h-tetrazol-5-yl)benzamide Chemical compound CC1=CC=C([N+]([O-])=O)C(C(=O)NC=2NN=NN=2)=C1 UXRJPOCIDAOHHW-UHFFFAOYSA-N 0.000 description 1
- QRRSIFNWHCKMSW-UHFFFAOYSA-N 5-methyl-2-nitrobenzoic acid Chemical compound CC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 QRRSIFNWHCKMSW-UHFFFAOYSA-N 0.000 description 1
- WAYVZRALCRKXTF-UHFFFAOYSA-N 5-methyl-2-nitrobenzoyl chloride Chemical compound CC1=CC=C([N+]([O-])=O)C(C(Cl)=O)=C1 WAYVZRALCRKXTF-UHFFFAOYSA-N 0.000 description 1
- DGDAVTPQCQXLGU-UHFFFAOYSA-N 5437-38-7 Chemical compound CC1=CC=CC(C(O)=O)=C1[N+]([O-])=O DGDAVTPQCQXLGU-UHFFFAOYSA-N 0.000 description 1
- XAICGUSPSFQKFM-UHFFFAOYSA-N 6-chloro-3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical compound O=C1C2=CC(Cl)=CC=C2N=CN1C1=NN=NN1 XAICGUSPSFQKFM-UHFFFAOYSA-N 0.000 description 1
- IVHOITKIJUJZKA-UHFFFAOYSA-N 6-methyl-3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical compound O=C1C2=CC(C)=CC=C2N=CN1C1=NN=NN1 IVHOITKIJUJZKA-UHFFFAOYSA-N 0.000 description 1
- NRZWECORTTWSEF-UHFFFAOYSA-N 6-nitro-1,3-benzodioxole-5-carbaldehyde Chemical compound C1=C(C=O)C([N+](=O)[O-])=CC2=C1OCO2 NRZWECORTTWSEF-UHFFFAOYSA-N 0.000 description 1
- ZOVGDBZRBILXPG-UHFFFAOYSA-N 6-nitro-1,3-benzodioxole-5-carbonyl chloride Chemical compound C1=C(C(Cl)=O)C([N+](=O)[O-])=CC2=C1OCO2 ZOVGDBZRBILXPG-UHFFFAOYSA-N 0.000 description 1
- WDENDHPXVZFMMC-UHFFFAOYSA-N 6-nitro-n-(2h-tetrazol-5-yl)-1,3-benzodioxole-5-carboxamide Chemical compound [O-][N+](=O)C1=CC=2OCOC=2C=C1C(=O)NC1=NN=NN1 WDENDHPXVZFMMC-UHFFFAOYSA-N 0.000 description 1
- WHANUZVJGJCMAX-UHFFFAOYSA-N 8-methyl-3-(2h-tetrazol-5-yl)quinazolin-4-one Chemical compound CC1=CC=CC(C2=O)=C1N=CN2C1=NN=NN1 WHANUZVJGJCMAX-UHFFFAOYSA-N 0.000 description 1
- 241000497851 Anaphes Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- SZGPJHJDNRNHIP-UHFFFAOYSA-N [Cr].[Na].[Na] Chemical compound [Cr].[Na].[Na] SZGPJHJDNRNHIP-UHFFFAOYSA-N 0.000 description 1
- ATNOAWAQFYGAOY-GPTZEZBUSA-J [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 Chemical compound [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 ATNOAWAQFYGAOY-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940047135 glycate Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BQFPCTXLBRVFJL-UHFFFAOYSA-N triethoxymethylbenzene Chemical compound CCOC(OCC)(OCC)C1=CC=CC=C1 BQFPCTXLBRVFJL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Adhesive Tapes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Materials For Photolithography (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/340,577 US4419357A (en) | 1982-01-18 | 1982-01-18 | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO830115L true NO830115L (no) | 1983-07-19 |
Family
ID=23333997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO830115A NO830115L (no) | 1982-01-18 | 1983-01-14 | Fremgangsmaate ved fremstilling av 3-(1h-tetrazol)-5-yl)-4(3h)-kinazolinoner |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4419357A (fr) |
| EP (1) | EP0086340B1 (fr) |
| JP (1) | JPS58124783A (fr) |
| KR (1) | KR880002358B1 (fr) |
| AT (1) | ATE18908T1 (fr) |
| AU (2) | AU555629B2 (fr) |
| CA (1) | CA1254204A (fr) |
| DE (1) | DE3362735D1 (fr) |
| DK (1) | DK159271C (fr) |
| ES (1) | ES8501758A1 (fr) |
| GB (2) | GB2113220B (fr) |
| GR (1) | GR77393B (fr) |
| IE (1) | IE54441B1 (fr) |
| IL (1) | IL67686A (fr) |
| NO (1) | NO830115L (fr) |
| NZ (1) | NZ203034A (fr) |
| PH (1) | PH18222A (fr) |
| ZA (1) | ZA83240B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419357A (en) * | 1982-01-18 | 1983-12-06 | The Dow Chemical Company | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones |
| US4644065A (en) | 1984-05-15 | 1987-02-17 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of 4(3H)-quinazolinones |
| GB8429739D0 (en) * | 1984-11-24 | 1985-01-03 | Fbc Ltd | Fungicides |
| US4761474A (en) * | 1986-02-25 | 1988-08-02 | Merrell Dow Pharmaceuticals Inc. | 3-(1H-tetrazol-5-yl)thieno[2,3-d]pyrimidin-4(3H)-ones |
| US4757075A (en) * | 1986-10-14 | 1988-07-12 | Merrell Dow Pharmaceuticals Inc. | Tetrazolylquinazolinones as anti-hyperuricemic agents |
| US8975288B2 (en) * | 2012-04-10 | 2015-03-10 | The Penn State Research Foundation | F2 derivatives as antibacterial agents |
| JP6141408B2 (ja) * | 2012-04-27 | 2017-06-07 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 置換型ｎ−（テトラゾール−５−イル）−およびｎ−（トリアゾール−５−イル）アリールカルボキサミド化合物ならびに除草剤としてのそれらの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH364040A (fr) * | 1960-04-19 | 1962-08-31 | Ipa Anstalt | Dispositif de détection pour vérifier si un élément d'une installation électrique est sous tension |
| US4035368A (en) * | 1975-04-02 | 1977-07-12 | Riker Laboratories, Inc. | Substituted 3-(1H-tetrazol-5-yl)-quinoline compounds |
| GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| AU508970B2 (en) * | 1976-02-13 | 1980-04-17 | Bristol-Myers Company | Tetrazole derivatives |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4209620A (en) * | 1978-06-19 | 1980-06-24 | Bristol-Myers Company | Substituted 3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives having antiallergy activity |
| NZ192392A (en) * | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
| GB2095240A (en) * | 1981-03-05 | 1982-09-29 | Fujisawa Pharmaceutical Co | Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| US4419357A (en) * | 1982-01-18 | 1983-12-06 | The Dow Chemical Company | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones |
-
1982
- 1982-01-18 US US06/340,577 patent/US4419357A/en not_active Expired - Lifetime
-
1983
- 1983-01-13 ZA ZA83240A patent/ZA83240B/xx unknown
- 1983-01-13 PH PH28385A patent/PH18222A/en unknown
- 1983-01-14 GB GB08300957A patent/GB2113220B/en not_active Expired
- 1983-01-14 AU AU10377/83A patent/AU555629B2/en not_active Expired
- 1983-01-14 NZ NZ203034A patent/NZ203034A/en unknown
- 1983-01-14 CA CA000419538A patent/CA1254204A/fr not_active Expired
- 1983-01-14 NO NO830115A patent/NO830115L/no unknown
- 1983-01-14 IL IL67686A patent/IL67686A/xx not_active IP Right Cessation
- 1983-01-14 ES ES519005A patent/ES8501758A1/es not_active Expired
- 1983-01-17 DK DK016783A patent/DK159271C/da not_active IP Right Cessation
- 1983-01-17 JP JP58004311A patent/JPS58124783A/ja active Granted
- 1983-01-17 IE IE78/83A patent/IE54441B1/en not_active IP Right Cessation
- 1983-01-17 EP EP83100341A patent/EP0086340B1/fr not_active Expired
- 1983-01-17 DE DE8383100341T patent/DE3362735D1/de not_active Expired
- 1983-01-17 AT AT83100341T patent/ATE18908T1/de not_active IP Right Cessation
- 1983-01-17 GR GR70275A patent/GR77393B/el unknown
- 1983-01-18 KR KR1019830000162A patent/KR880002358B1/ko not_active IP Right Cessation
-
1984
- 1984-11-09 GB GB08428402A patent/GB2170800B/en not_active Expired
-
1986
- 1986-08-15 AU AU61517/86A patent/AU570852B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0450310B2 (fr) | 1992-08-13 |
| KR840003250A (ko) | 1984-08-20 |
| DE3362735D1 (de) | 1986-05-07 |
| GR77393B (fr) | 1984-09-11 |
| NZ203034A (en) | 1985-09-13 |
| CA1254204A (fr) | 1989-05-16 |
| DK159271C (da) | 1991-02-18 |
| EP0086340A1 (fr) | 1983-08-24 |
| DK16783D0 (da) | 1983-01-17 |
| GB8428402D0 (en) | 1984-12-19 |
| AU555629B2 (en) | 1986-10-02 |
| GB2113220B (en) | 1985-09-04 |
| AU1037783A (en) | 1983-07-28 |
| IE830078L (en) | 1983-07-18 |
| AU6151786A (en) | 1986-12-11 |
| ES519005A0 (es) | 1984-12-16 |
| DK159271B (da) | 1990-09-24 |
| KR880002358B1 (ko) | 1988-10-29 |
| GB2170800A (en) | 1986-08-13 |
| IL67686A0 (en) | 1983-05-15 |
| GB2170800B (en) | 1987-01-07 |
| JPS58124783A (ja) | 1983-07-25 |
| EP0086340B1 (fr) | 1986-04-02 |
| ZA83240B (en) | 1983-10-26 |
| ATE18908T1 (de) | 1986-04-15 |
| ES8501758A1 (es) | 1984-12-16 |
| AU570852B2 (en) | 1988-03-24 |
| PH18222A (en) | 1985-04-30 |
| GB8300957D0 (en) | 1983-02-16 |
| DK16783A (da) | 1983-07-19 |
| IL67686A (en) | 1985-12-31 |
| IE54441B1 (en) | 1989-10-11 |
| US4419357A (en) | 1983-12-06 |
| GB2113220A (en) | 1983-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2740588A1 (de) | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -chinolin-2-carbon- saeuren und deren derivate sowie pharmazeutische zubereitungen, die diese verbindungen enthalten | |
| NO830115L (no) | Fremgangsmaate ved fremstilling av 3-(1h-tetrazol)-5-yl)-4(3h)-kinazolinoner | |
| NO841157L (no) | Fremgangsmaate ved fremstilling av nye (1h-tetrazol-5-yl)-2(1h)-kinoliner | |
| US4267332A (en) | 3-(Tetrazol-5-yl)-1-azaxanthones | |
| CA1252100A (fr) | (1h-tetrazol-5-yl)tetrazolo[1,5-a]-quinoleines et composes apparentes | |
| JPS63183581A (ja) | ピリド〔１，２−ａ〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬 | |
| EP0132788B1 (fr) | 2-(Formylamino)-N-(1H-tétrazol-5-yl)benzamide | |
| NO842026L (no) | Fremgangsmaate ved fremstilling av substituerte 1,2,3-triazino(4`,5`:4,5)-thieno(2,3-b)kinolin-4(3h)-oner | |
| NO168641B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive carbamater og oxalamider av amino-n-(1h-tetrazol-5-yl)benzamider. | |
| JPH0374669B2 (fr) | ||
| NZ210870A (en) | Substituted 2-amino-n-(1h-tetrazol-5-yl)benzamide derivatives | |
| US4593099A (en) | (Tetrazolyl) thienopyridinones | |
| EP0210648A1 (fr) | Acides chloro-5 s-triazolo[4,3-a]pyridinecarboxyliques-7 | |
| JPH0473436B2 (fr) | ||
| JPS6310155B2 (fr) | ||
| NO149503B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte tetrazoler. |